Can OMER stock retain Novo Nordisk driven gains over the long-term?

Core Viewpoint - Omeros Corporation's stock surged over 150% following the announcement of a licensing agreement with Novo Nordisk, potentially worth up to $2.1 billion [1] Company Summary - Omeros Corporation (NASDAQ: OMER) has entered into a new licensing agreement with Novo Nordisk, which is headquartered in Bagsværd [1] - The agreement has a total potential value of $2.1 billion, indicating significant financial implications for Omeros [1] Market Reaction - The stock price of Omeros Corporation experienced a dramatic increase of over 150% in response to the licensing agreement announcement [1]